The SHH subtype also harbors MYCN-amplified (7.7–16.7%) and MYCL-amplified tumors (2.3%) [37,61,62,63], although the biological role of L-MYC in medulloblastoma is unknown (Figure 1e). This evidence concerns the gene MYCN and medulloblastoma.